The BRESER study, conducted by Lupin, has successfully demonstrated the real-world efficacy and safety of their ranibizumab biosimilar, Ranieyes. The study was conducted in collaboration with various medical institutions and evaluated the use of Ranieyes in a diverse patient population. The results showed that Ranieyes was effective in treating various retinal disorders, including age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.

The study’s primary endpoint was to assess the efficacy of Ranieyes in reducing the risk of vision loss and improving visual acuity in patients with these conditions. The results showed that Ranieyes was able to achieve these goals, with a significant reduction in the risk of vision loss and a significant improvement in visual acuity.

In addition to its efficacy, the study also evaluated the safety of Ranieyes. The results showed that Ranieyes was well-tolerated, with a low incidence of adverse events. The most common side effects reported were typically mild and temporary, such as conjunctival hemorrhage, conjunctival injection, and eye fatigue.

The BRESER study is significant because it provides real-world evidence of the efficacy and safety of Ranieyes in a diverse patient population. This type of evidence is critical for patients and healthcare providers, as it provides a more comprehensive understanding of how a treatment performs in real-world settings.

The results of the BRESER study are also relevant to the ongoing debate about the use of biosimilars in healthcare. Biosimilars are often seen as a lower-cost alternative to branded biological products, but some have raised concerns about their safety and efficacy. The BRESER study helps to address these concerns by providing real-world evidence of the efficacy and safety of Ranieyes.

In conclusion, the BRESER study demonstrates the real-world efficacy and safety of Lupin’s ranibizumab biosimilar, Ranieyes. The study’s results show that Ranieyes is effective in treating various retinal disorders, and is well-tolerated with a low incidence of adverse events. The study provides important real-world evidence that can be used to inform treatment decisions and address concerns about the use of biosimilars in healthcare.

Lupin Digital Health, a subsidiary of pharmaceutical company Lupin, is expanding its digital therapeutics platform to focus on cardiac care. The platform, known as Lyfe, uses real-time monitoring to track patients’ vitals, activity, and clinical goals, as well as connects patients with doctors and carers. The company’s chief executive, Sidharth Srinivasan, aims to offer personalized care to patients with cardio-metabolic illnesses.

Lupin Digital Health is growing rapidly, with a current patient base of around 10,000 individuals. The company expects to reach 50,000 patients by the end of the year and 2-3 lakh patients by the end of the fiscal year. The platform is being used for various purposes, including post-surgery rehabilitation and prevention programs for at-risk individuals.

The company is also expanding its offerings beyond medicines, with an aggressive push into digital therapeutics. Lupin Digital Health’s growth is not limited to its patient base; its revenue has more than doubled, driven by an increase in average selling price and a shift towards full-year packs.

Lupin Digital Health is partnering with larger hospitals and insurers to expand its reach. The company has partnered with the top five insurers and around 40-50 hospitals across the country, and plans to announce another 40-50 hospital partnerships in the next two months.

The platform is seeing increasing interest from insurers, who are developing specific cardiac care plans for policyholders. Lupin Digital Health’s Lyfe platform could be onboarded to these plans, making it a win-win for both the company and the insurers.

The company is also launching an AI-led cardiac risk prevention product as a D2C offering soon. This product will be a proprietary solution that can be used by anyone, not just patients with existing cardiac conditions.

Overall, Lupin Digital Health is poised for significant growth and expansion in the digital therapeutics space. Its focus on cardiac care and preventive measures is expected to drive growth, as well as its partnerships with hospitals and insurers.

Lupin Healthcare (UK) Limited, a subsidiary of global pharmaceutical company Lupin Limited, has acquired Renascience Pharma Limited, a UK-based pharmaceutical company specializing in four key specialty products. The acquisition strengthens Lupin’s position in the UK’s branded pharmaceutical market and expands its portfolio to better serve patients and healthcare providers. Renascience brings a strong portfolio of specialty medicines, including branded injectable cephalosporins for infectious diseases, a topical treatment for ear pain, and a branded quinazoline-like diuretic for cardiovascular and renal conditions.

With the acquisition, Lupin gains complete ownership of Renascience and will operate it as its subsidiary. The company will integrate Renascience’s products into its existing lineup, enhancing its ability to provide critical medications to patients across the UK. Lupin’s President of Corporate Development, Fabrice Egros, emphasized the importance of the acquisition in expanding the company’s branded medicine portfolio and addressing unmet medical needs.

Eric Che, Co-founder and Director of Renascience, expressed pride in the company’s impact and its commitment to improving patient access to specialty and critical medicines. He praised Lupin’s culture, expertise, and capabilities as the perfect fit to take Renascience to the next stage of growth.

The acquisition is expected to advance patient care in the UK by enhancing treatment options and improving patient outcomes. Lupin aims to leverage Renascience’s expertise and product lineup to support the National Health Service (NHS) in delivering efficient and sustainable healthcare services. Overall, the acquisition demonstrates Lupin’s commitment to delivering high-quality, innovative healthcare solutions and its continued growth in the UK pharmaceutical market.

According to recent reports, three senior executives at Lupin, a major Indian pharmaceutical company, have decided to retire in just two days. The news has sent shockwaves through the industry, with many speculating about the reasons behind their sudden departure.

Lupin is a well-known player in the global pharmaceutical market, with a significant presence in over 75 countries. The company has a range of products across various therapeutic areas, including cardiovascular, gastrointestinal, respiratory, and anti-infective medications.

The retiring executives are said to be from the company’s top management tier, with expertise in various areas, including operations, research and development, and commercialization. Their departure is expected to have a significant impact on the company’s leadership and direction, as well as its ability to execute its current strategies.

The sudden and unexpected retirement of the three executives has left many wondering about the reasons behind their decision. Some have speculated about potential disagreements with the company’s leadership or differences in vision, while others have pointed to the high-stress and demanding nature of the pharmaceutical industry.

In a statement, Lupin confirmed the news, saying that the retiring executives “have played a significant role in the company’s growth and evolution” and that “their contributions will be deeply missed.” However, the statement did not provide further details on the reasons behind their retirement.

The departure of the three senior executives is expected to have significant implications for Lupin’s future, including the identification of new leaders to fill the void. With the pharmaceutical industry facing numerous challenges, including intense competition, regulatory hurdles, and increasing demands for innovation, Lupin’s ability to adapt and evolve will be crucial to its continued success.

Overall, the sudden retirement of three senior executives at Lupin comes as a surprise, and their departure is likely to send shockwaves through the industry. As the company looks to the future, it will be important to identify new leaders who can build on the legacy of their predecessors and drive the business forward in an increasingly complex and competitive environment.

Here is a 400-word summary of the content:

Lupin Digital Health, a leading digital therapeutics platform in India, has launched a comprehensive Post-Procedure Home-Based Care Guide at the India Live conference in Mumbai. The guide is based on the American College of Cardiology’s “Home-Based Care Workbook” and has been developed in collaboration with renowned cardiologists. The guide provides patients and caregivers with essential information and practical advice to manage post-procedure recovery at home, covering conditions such as heart failure, arrhythmia, and coronary artery bypass grafting.

The guide is designed to help patients understand their recovery process, recognize potential complications, manage medications, and make necessary lifestyle adjustments. It also provides access to cardiac rehabilitation resources. The development of this guide underscores Lupin Digital Health’s commitment to delivering evidence-based, high-quality educational resources that enhance patient recovery and long-term well-being.

The guide is a valuable resource for patients and caregivers, as it provides structured guidance that simplifies recovery and enhances post-procedure care at home. According to Dr. Rajeev Sibal, President – India Region Formulations, Lupin, empowering patients with the right knowledge is crucial for better health outcomes.

The launch of this guide is a significant step towards improving patient recovery and well-being following cardiac procedures. As the burden of cardiovascular diseases continues to rise, it is essential to improve home-based care. The guide offers patients the support they need to navigate recovery with confidence, reducing hospital readmissions and ensuring a smoother transition from hospital to home.

Lupin Digital Health is committed to delivering evidence-based, high-quality educational resources that enhance patient recovery and long-term well-being. With this guide, the company is redefining chronic disease management in India and setting a new standard for patient care. The guide is available on the company’s website, and patients and caregivers can access it to improve their recovery and overall quality of life.

Here is a summary of the content to 400 words:

Lupin Digital Health, a leading digital therapeutics platform, has launched a comprehensive post-procedure home-based care guide in collaboration with the American College of Cardiology (ACC). The guide is designed to improve patient recovery and well-being following cardiac procedures such as Heart Failure, Arrhythmia, Percutaneous Coronary Intervention (PCI), and Coronary Artery Bypass Grafting (CABG). The guide is based on the ACC’s “Home-Based Care Workbook” and is co-authored by prominent cardiologists Dr. JPS Sawhney, Dr. Prafulla Kerkar, Dr. Harikrishnan, and Dr. Aditya Kapoor, along with Dr. Chetan Gharat.

The guide provides patients and caregivers with essential information and practical advice on managing post-procedure recovery at home, including understanding the recovery process, recognizing potential complications, managing medications, making lifestyle adjustments, and accessing cardiac rehabilitation resources. According to Rajeev Sibal, President – India Region Formulations at Lupin, the guide is designed to empower patients with the right knowledge, which is crucial for better health outcomes.

Sidharth Srinivasan, CEO of Lupin Digital Health, emphasized the importance of improving home-based care, stating that it is no longer optional, but essential, especially in light of the rising burden of cardiovascular diseases. Dr. Prafulla Kerkar, Senior Interventional Cardiologist, Asian Heart Institute, highlighted the importance of structured recovery, noting that the transition from hospital to home can be a vulnerable period for cardiac patients.

The launch of this guide underscores Lupin Digital Health’s commitment to delivering evidence-based, high-quality educational resources that enhance patient recovery and long-term well-being. The initiative is part of Lupin’s efforts to bridge gaps in chronic disease management and ensure that patients receive seamless care beyond hospital discharge.

Here is a 400-word summary of the content:

Nanomi B.V., a Dutch subsidiary of Lupin Limited, a global pharmaceutical major, has won the prestigious CMO Award for Life Science Leadership in Drug Delivery. This award was given during the DCAT week in New York. Nanomi’s innovative approach to drug delivery has set new standards in the industry, and this recognition serves as a motivational boost to continue revolutionizing healthcare.

Dr. Shahin Fesharaki, Global Chief Scientific Officer at Lupin, stated that this recognition highlights Nanomi’s commitment to advancing science and underscores its pioneering efforts in drug delivery. Lupin remains dedicated to innovation that enables the delivery of high-quality medicines, which significantly improve patient outcomes.

The CMO Leadership Awards are presented by Outsourced Pharma and Life Science Connect, with research by Orientation Marketing. These awards recognize top outsourcing partners, based on feedback from sponsor companies who outsource manufacturing. This year marks the first year the CMO Leadership Award is juried.

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. The company specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. With 15 state-of-the-art manufacturing sites and 7 research centers globally, Lupin has a dedicated workforce of over 23,000 professionals.

Lupin is committed to improving patient health outcomes through its subsidiaries, including Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. To learn more about Lupin, visit www.lupin.com or follow them on LinkedIn. To learn more about Nanomi, visit www.nanomi.com or follow them on LinkedIn.

Lupin, a global pharmaceutical company, has been awarded the EcoVadis Silver Medal for sustainability excellence. The award recognizes Lupin’s commitment to sustainability across its entire value chain, from sourcing and production to distribution and end-of-life environmental management.

EcoVadis is a leading platform for sustainability ratings and performance improvement, providing a comprehensive assessment of companies’ environmental, social, and governance (ESG) performance. The Silver Medal is the second-highest award offered by EcoVadis, indicating that Lupin has demonstrated a strong track record of sustainability performance over the past year.

Lupin’s sustainability efforts focus on six key areas: environment, social, governance (ESG), value chain engagement, community development, and stakeholder engagement. The company has made significant progress in reducing its environmental impact, including a 25% reduction in energy consumption and a 30% decrease in greenhouse gas emissions since 2015.

In addition, Lupin has implemented various social initiatives, such as employee engagement programs, diversity and inclusion initiatives, and community development projects. The company has also strengthened its governance structure, ensuring transparency and accountability in its decision-making processes.

The award is a testament to Lupin’s commitment to sustainability and its efforts to create a positive impact on the environment, society, and its stakeholders. The company plans to continue its sustainability journey, exploring new opportunities for growth while minimizing its environmental footprint and promoting positive social change.

The EcoVadis Silver Medal is a milestone achievement for Lupin, demonstrating its leadership in the pharmaceutical industry. The award also reinforces the company’s commitment to transparency, accountability, and continuous improvement. With this recognition, Lupin aims to inspire other organizations to follow its lead in embracing sustainability as a key business strategy.

Lupin Limited, a pharmaceutical company, has received tentative approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application for Amifampridine Tablets, 10mg. This product is indicated for the treatment of Lambert-Eaton myasthenic syndrome in adults and pediatric patients 6 years of age and older. The drug is a generic version of Firdapse Tablets, 10mg, which has an estimated global net sale of $306 million for the fiscal year ended December 31, 2024.

The product will be manufactured at Lupin’s Goa facility in India, making it a significant milestone for the company. The tentative approval is a crucial step towards making the drug available to patients at an affordable price, as it allows the company to market and sell the product in the US market. The drug is expected to be a major contributor to the company’s revenue, given its high estimated global net sales.

Lambert-Eaton myasthenic syndrome is a rare autoimmune disorder that affects the nervous system and can cause muscle weakness and paralysis. The condition can significantly impact daily life, making it essential to have effective treatment options available. With this approval, Lupin’s Amifampridine Tablets, 10mg, is set to provide a cost-effective alternative to existing treatment options, thereby improving patient access to the medication.

The approval is a testament to Lupin’s commitment to providing high-quality and affordable generic medicines to patients worldwide. The company’s Goa facility has a reputation for producing high-quality products, and this approval is a reflection of the facility’s capabilities. Overall, this approval is a significant achievement for Lupin, and the company is expected to benefit significantly from the sale of this product in the US market.

The US Food and Drug Administration (USFDA) has granted tentative approval to Lupin Ltd’s Abbreviated New Drug Application (ANDA) for Amifampridine Tablets, 10 mg, for the treatment of Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune neuromuscular disorder that affects communication between nerve and muscle. This approval allows Lupin to enter the market and offers a major market opportunity, as the reference drug Firdapse had global net sales of $306 million in 2024. The tablets will be manufactured at Lupin’s facility in Goa, boosting the company’s global manufacturing capabilities and commitment to providing affordable medications.

While the tentative approval meets all quality, safety, and efficacy requirements, final approval will depend on the expiration of or resolution of patent or exclusivity rights related to Firdapse. This approval aligns with Lupin’s focus on developing and expanding its presence in the US market. The successful launch of Amifampridine Tablets, 10 mg, will allow Lupin to capitalize on the large market for LEMS treatment, providing a major boost to its business and financials. With this approval, Lupin reinforces its position as a leading player in the global pharmaceutical industry, committed to delivering high-quality, affordable medications to patients worldwide.

Lupin, a leading pharmaceutical company, has announced the launch of AjaDuo, a fixed-dose combination (FDC) of empagliflozin and linagliptin, at an affordable price. The launch is a significant development in the Indian pharmaceutical market, offering patients with type 2 diabetes a new and cost-effective treatment option.

AjaDuo is a combination therapy that combines the benefits of two medications: empagliflozin, an SGLT-2 inhibitor, and linagliptin, a DPP-4 inhibitor. This combination has been shown to improve glycemic control and reduce blood sugar levels. The fixed-dose combination is expected to offer benefits such as improved patient adherence, reduced pill burden, and enhanced convenience.

Lupin’s AjaDuo is priced competitively, making it an attractive option for patients with type 2 diabetes who require combination therapy. The company’s efforts to launch affordable medications are aimed at increasing access to quality healthcare, particularly in developing countries like India where healthcare infrastructure is often limited.

The launch of AjaDuo is a strategic move by Lupin to expand its presence in the diabetes market, which is one of the fastest-growing therapeutic segments globally. The company’s portfolio already includes several popular diabetes drugs, and the launch of AjaDuo is expected to further strengthen its position in this space.

The availability of AjaDuo at an affordable price is expected to benefit millions of patients with type 2 diabetes, who may not have access to branded treatments or may be forced to compromise on their treatment due to cost constraints. The launch is a significant step towards increasing access to quality healthcare for patients, especially in emerging markets.

Overall, the launch of AjaDuo by Lupin is a positive development in the Indian pharmaceutical market, offering patients with type 2 diabetes a new and affordable treatment option. The company’s initiatives to make high-quality medications accessible at affordable prices are likely to benefit millions of patients across the country.